Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document
The FDA released briefing documents, raising concerns over whether Capricor’s lead therapy, Deramiocel, has demonstrated sufficient effectiveness in treating cardiomyopathy in patients with Duchenne muscular dystrophy.